CONVENIA is indicated for the treatment of skin infections, bacterial or fungal, in dogs and cats. The infections include wounds, abscesses, cellulitis, and oncologic-related skin infections, and is contraindicated in dogs and cats with known or suspected hypersensitivity to β-lactam antibiotics. Dosage should be guided by sensitivity studies and general principles of therapy. Initial antimicrobial therapy should be based on sensitivity studies performed during the preclinical development of drug resistance. Treatment should be continued for a minimum of 7 days following the complete resolution of clinical signs.

**CONTRAINDICATIONS:**

CONVENIA is contraindicated in dogs and cats with known or suspected hypersensitivity to β-lactam antibiotics. It is also contraindicated in dogs and cats with known or suspected infections caused by fungi, viruses, protozoal, or parasitic agents. The safety of CONVENIA in pregnant, nursing, or lactating animals, as well as in animals with known or suspected allergies to β-lactam antibiotics, has not been established. The drug should be used with caution in animals with a history of hemolytic anemia, salivation, pruritus, lethargy, vomiting, diarrhea, and inappetance.

**WARNINGS:**

Not for use in humans. Keep this and all other drugs out of reach of children. Avoid direct contact with the skin and mucous membranes. In case of accidental contact, wash with soap and water. Do not incinerate containers.

**PRECAUTIONS:**

Avoid contact with eyes and mucous membranes. Do not use in animals with known or suspected allergy to cephalosporins or β-lactam antibiotics. The use of concomitant antibiotics should be guided by individual patient needs. The administration of cephalosporins and non-steroidal anti-inflammatory drugs (NSAIDs) may result in an increase in free concentrations of carprofen, furosemide, doxycycline and gentamicin. This increase in free concentrations may result in an increase in toxicity and adverse reactions.

**ADVERSE REACTIONS:**

The most common adverse reactions reported in dogs and cats include vomiting, diarrhea, anorexia, and decreased appetite. Other adverse reactions reported in dogs include lethargy, inappetance, and in some cases, a decrease in body weight. In cats, adverse reactions have included lethargy, inappetance, and decreased body weight. In both species, the adverse reactions were generally mild to moderate in severity.

**PHARMACOKINETICS:**

The pharmacokinetics of cefovecin in dogs and cats have been studied. Following a single subcutaneous injection of 8 mg/kg body weight, the peak plasma concentration of cefovecin was achieved at 0.7-1.2 hours. The plasma half-life of cefovecin was 12-14 days. The mean plasma concentration-time profile of cefovecin was less than 25% of the peak concentration at 24 hours after dosing.

**ANIMAL SAFETY:**

Animals treated with CONVENIA have not been involved in any adverse drug reactions. The drug has been used in a variety of species, including dogs and cats, and has not been associated with any significant adverse reactions. The drug is safe for use in animals with a history of hemolytic anemia, salivation, pruritus, lethargy, vomiting, diarrhea, and inappetance.

**REFERENCES:**